WuXi AppTec
http://www.wuxiapptec.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From WuXi AppTec
China Further Tightens Oversight Of Human Genetic Research
Although the latest implementing details classify many aspects of human genetic resource handling and transfer, foreign entities are severely restricted from developing gene and gene-editing therapies in China. Legal experts say the changes combined with data transfer and recent cybersecurity legislation pose additional challenges to life science companies operating in the country.
'Still Bad Out There' - Drug Makers In APAC Prepare For Worst Before It Gets Better
Cross-border deals are down and investment has dried up, while geopolitical tensions have started hitting the Chinese biotech sector in unprecedented ways. Biopharma firms are expecting more rainy days ahead and are embracing new fundraising and deal-making approaches to survive and thrive.
China New Government Policies Taking Shape As Two Sessions Underway
Moderate growth goal and lingering impact from COVID policies dampen prospects of a quick recovery for China.
Go Global Or Stay Home? Geopolitics, Funding Crunch May Force China Biotechs To Choose
Having been used to navigating the Pacific with few obstacles, biotech companies taking advantage of Chinese resources and US innovation now face ballooning tensions between the two countries, which along with narrowing funding channels will increasingly force them to decide where to place their bets in the world’s largest economies.
Company Information
- Industry
- Contract Research Organization-CRO
- Laboratory Testing Services
- Medical Devices
- Pharmaceuticals
- Services
-
Biotechnology
-
Drug Discovery Technologies
- ADMET
- Bioinformatics
-
Drug Discovery Technologies
- Other Names / Subsidiaries
-
- Crelux GmbH
- Faxian Therapeutics
- JW Biotechnology (Shanghai) Co., Ltd
- OXGENE
- ResearchPoint Global
- STA Pharmaceutical Co., Ltd.
- WuXi PharmaTech
- WuXi Merger Limited
- XenoBiotic Laboratories, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice